产品
编 号：F026936
分子式：C16H15F3O
分子量：280.28
分子式：C16H15F3O
分子量：280.28
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1071001-09-6
产品详情
生物活性：
FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes.
体内研究：
FKGK18 (20 mg/kg; i.p. three times per week from 10 days until euthanasia) reduces diabetes incidence.Animal Model:10-day-old female NOD mice
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg three times per week; from 10 days until euthanasia
Result:Reduced diabetes incidence and maintained better glucose homeostasis.
体外研究：
FKGK18 (1 nM; 1 h) inhibits glucose-stimulated insulin secretion (GSIS) and prostaglandin E2 (PGE2) generation.FKGK18 (0.1-10 nM; 24 h) inhibits beta-cell apoptosis.FKGK18 (0.1-10 μM; 24 h) affects immune cells function and influences B-cell survival.
FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes.
体内研究：
FKGK18 (20 mg/kg; i.p. three times per week from 10 days until euthanasia) reduces diabetes incidence.Animal Model:10-day-old female NOD mice
Dosage:20 mg/kg
Administration:Intraperitoneal injection; 20 mg/kg three times per week; from 10 days until euthanasia
Result:Reduced diabetes incidence and maintained better glucose homeostasis.
体外研究：
FKGK18 (1 nM; 1 h) inhibits glucose-stimulated insulin secretion (GSIS) and prostaglandin E2 (PGE2) generation.FKGK18 (0.1-10 nM; 24 h) inhibits beta-cell apoptosis.FKGK18 (0.1-10 μM; 24 h) affects immune cells function and influences B-cell survival.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备